Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 5,019	$ 3,280	$ 15,802	$ 7,352
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	2,177	1,219	7,064	3,126
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,842	$ 2,061	$ 8,738	$ 4,226